22.06.2017 • News • Dede Willams • MDI • BorsodChem

Wanhua and BorsodChem Invest in European MDI Storage

Chinese chemical group Wanhua and its Hungarian subsidiary BorsodChem have invested in a new bulk storage facility for the isocyanate MDI at Rotterdam in the Netherlands. The facility, which will house two tanks, will be located at a site operated by leading chemical storage service provider LBC Tank Terminals.

The companies cite growing demand for MDI in Europe and the need to improve flexibility of supplies to customers in the region. Product stored at Rotterdam will be imported from China for the most part.

Wanhua is regarded as world’s largest MDI producer with more than 2,000 t/y of capacity worldwide. The Chinese company took over BorsodChem, the leading producer of MDI and TDI in central and eastern Europe, in 2011.

Interview

Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Innovation Pitch

Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Top-Feature

IMCD Deutschland GmbH

Fostering Innovation and Collaboration

Ecocool GmbH

Transport Logistic: Ecocool Presents Packaging Solutions for Pharmaceutical Transports

Evonik Industries AG

Maximize the Potential of Spent Hydroprocessing Catalysts

CHEManager International c/o Wiley-VCH GmbH

Digitalization in the Chemical Industry

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

19.03.2025 • News

Wanhua and BorsodChem Invest in European MDI Storage